Lonza has acquired HansaBioMed Life Sciences and has invested into Exosomics Siena to develop next-generation research, therapeutic and diagnostic applications based on exosomes Exosomes technology will leverage Lonza’s portfolio of drug discovery products, as well as its development and manufacturing ...
Read More »Integrated isolation and quantitative analysis of exosome shuttled proteins and nucleic acids using immunocapture approaches
Clinical implementation of exosome based diagnostic and therapeutic applications is still limited by the lack of standardized technologies that integrate efficient isolation of exosomes with comprehensive detection of relevant biomarkers. Conventional methods for exosome isolation based on their physical properties ...
Read More »